Search research articles
Contact Us
Filters
Showing results (121-130 of 133) with videos related to
Page
of 14
Sort By:
JAMA
|
February 11, 2015
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial
, Karl Kieburtz, Barbara C Tilley, et al.
Parkinsonism & Related Disorders
|
April 8, 2018
Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients
Matej Skorvanek, Pablo Martinez-Martin, Norbert Kovacs, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
July 24, 2008
Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study
Christopher F McNicoll, Jeanne C Latourelle, Marcy E MacDonald, et al.
Human Genetics
|
July 1, 2008
Replication of association between ELAVL4 and Parkinson disease: the GenePD study
Anita L DeStefano, Jeanne Latourelle, Mark F Lew, et al.
Movement Disorders Clinical Practice
|
October 27, 2018
Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration
Matej Skorvanek, Pablo Martinez-Martin, Norbert Kovacs, et al.
Neurology
|
August 18, 2017
National randomized controlled trial of virtual house calls for Parkinson disease
Christopher A Beck, Denise B Beran, Kevin M Biglan, et al.
Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association
|
February 18, 2016
National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers
E Ray Dorsey, Meredith A Achey, Christopher A Beck, et al.
BMC Medicine
|
November 7, 2008
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study
Jeanne C Latourelle, Mei Sun, Mark F Lew, et al.
Neurology
|
December 4, 2016
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
Andrew McGarry, Michael McDermott, Karl Kieburtz, et al.
Journal of Clinical Medicine
|
November 19, 2020
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial
Michael J Brownstein, Neal G Simon, Jeffrey D Long, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 133) with videos related to
Sort By:
Page
of 14
JAMA
|
February 11, 2015
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial
, Karl Kieburtz, Barbara C Tilley, et al.
Parkinsonism & Related Disorders
|
April 8, 2018
Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients
Matej Skorvanek, Pablo Martinez-Martin, Norbert Kovacs, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
July 24, 2008
Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study
Christopher F McNicoll, Jeanne C Latourelle, Marcy E MacDonald, et al.
Human Genetics
|
July 1, 2008
Replication of association between ELAVL4 and Parkinson disease: the GenePD study
Anita L DeStefano, Jeanne Latourelle, Mark F Lew, et al.
Movement Disorders Clinical Practice
|
October 27, 2018
Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration
Matej Skorvanek, Pablo Martinez-Martin, Norbert Kovacs, et al.
Neurology
|
August 18, 2017
National randomized controlled trial of virtual house calls for Parkinson disease
Christopher A Beck, Denise B Beran, Kevin M Biglan, et al.
Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association
|
February 18, 2016
National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers
E Ray Dorsey, Meredith A Achey, Christopher A Beck, et al.
BMC Medicine
|
November 7, 2008
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study
Jeanne C Latourelle, Mei Sun, Mark F Lew, et al.
Neurology
|
December 4, 2016
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
Andrew McGarry, Michael McDermott, Karl Kieburtz, et al.
Journal of Clinical Medicine
|
November 19, 2020
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial
Michael J Brownstein, Neal G Simon, Jeffrey D Long, et al.
Page
of 14